Dendreon completes $620 million public offering of Convertible Senior Notes

Client(s) Dendreon Corporation

Jones Day represented Dendreon Corporation, a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients, in connection with its issuance of $620 million of 2.875% Convertible Senior Notes due 2016 in a public offering underwritten by J.P. Morgan Securities LLC. In connection with the offering of the Notes, the underwriter purchased 1,787,100 outstanding shares of Dendreon's Common Stock from buyers of the Notes for distribution to the public in a registered offering to facilitate hedging by buyers of the Notes.